This is one that I've had my eye on ever since it IPO'ed in January and is probably the best investment you will ever see in your investing career. It's a sleeping giant and probably the safest yet highest potential return microcap stock on the market currently and easily has the ability to to go %200-%600+ overnight on 1 easily achievable announcement and could grow 50x-100x on approval of their drug IMX-110 that is crushing competitor Johnson and Johnson's fda approved drug 'Yondelis' in trials. Not only this but IMX-110 has been approved for RPDD (rare pediatric disease designation) which means that upon marketing approval they will receive a PRV (priority review voucher) which is a ticket that allows them to fast track fda review. These vouchers are worth $67m-$350m! That's at least over 2x their whole market cap just in a bonus when their drug is approved!!!! not to mention IMX-110 is a drug that addresses a $3B market with virtually no competition.
Now if you haven't noticed a lot rides on IMX-110, if it gets approved the company will be valued at $1B+ with PRV and IMMX-110; the market cap is just $30m currently… I will now show you why insiders have been so confident about IMX-110 getting FDA approval.
https://finance.yahoo.com/news/immixbio-imx-110-demonstrated-improved-124700236.html. This is the results against the leading FDA approved competitor… 75%-0% survival rate after 22 days…. remember there's literally a billion dollars riding on this being better than its competitors and we can see by these results they are light years ahead. The industry is also expected to grow from $3B to $6.5B by 2030.
The number 1 problem with companies that haven't started making revenue is their cash burn. IMMX raised $20m in their IPO and are only burning 2.6m/year in operation meaning they have over 7 years of cash burn before they need more funding. On top of that the CEO was so confident in their operations they actually went through a share repurchase for $1m just a few months after their IPO… this is unheard of for stocks especially in this sector. Insiders also bought a bunch of shares.
Also, it is great for a short squeeze candidate. Insiders own 62% of shares making float 5M shares. short float sits just above 8% and CTB %330.
TLDR; Insiders have done literally everything they could do to show how confident they are in their lead drug IMX-110 by share repurchase and by loading up themselves. The trial results for IMX-110 blew its fda approved competition out of the water. Upon approval IMMX immediately gets a PRV worth $67m-$350m and will have the only effective drug in a $3B industry expected to grow to $6.5B by 2030
Leave a Reply